After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
IMVT belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Immunovant Inc is $2.58B. A total of 1.14 million shares were traded on the day, compared to an average of 1.29M shares.
In the most recent transaction, Stout Jay S sold 2,805 shares of IMVT for 18.15 per share on Jul 23 ’25. After the transaction, the Chief Technology Officer now owns 204,919 company shares. In a previous transaction on Jul 23 ’25, Geffner Michael sold 2,385 shares at 18.15 per share. IMVT shares that Chief Medical Officer owns now total 221,825.
Among the insiders who sold shares, Geffner Michael disposed of 1,160 shares on Jul 09 ’25 at a per-share price of $17.24. This resulted in the Chief Medical Officer holding 224,210 shares of IMVT after the transaction. In another insider transaction, Stout Jay S sold 1,519 shares at $17.24 per share on Jul 09 ’25. Company shares held by the Chief Technology Officer now total 207,724.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, IMVT has a high of $34.47 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.72 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.74 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $3.56, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.41.
